Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Overexpression of osteopontin, αvβ3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer.

Jin Y, Tong DY, Chen JN, Feng ZY, Yang JY, Shao CK, Li JP.

PLoS One. 2012;7(10):e48575. doi: 10.1371/journal.pone.0048575. Epub 2012 Oct 31.

2.

Expressions of Osteopontin (OPN), ανβ3 and Pim-1 Associated with Poor Prognosis in Non-small Cell Lung Cancer (NSCLC).

Jin Y, Tong DY, Tang LY, Chen JN, Zhou J, Feng ZY, Shao CK.

Chin J Cancer Res. 2012 Jun;24(2):103-8. doi: 10.1007/s11670-012-0103-1.

3.

Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer.

Pang W, Tian X, Bai F, Han R, Wang J, Shen H, Zhang X, Liu Y, Yan X, Jiang F, Xing L.

Mol Cancer. 2014 Oct 24;13:240. doi: 10.1186/1476-4598-13-240.

4.

[Over-expression of osteopontin in non-small cell lung cancers: its clinical significance].

Hu Z, Xiao T, Lin DM, Guo SP, Zhang ZQ, Di XB, Cheng SJ, Gao YN.

Zhonghua Zhong Liu Za Zhi. 2007 Aug;29(8):591-5. Chinese.

PMID:
18210878
5.

Frequent down-regulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases.

Warnecke-Eberz U, Bollschweiler E, Drebber U, Pohl A, Baldus SE, Hoelscher AH, Metzger R.

Oncol Rep. 2008 Sep;20(3):619-24.

PMID:
18695914
6.

Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer.

Lin Q, Guo L, Lin G, Chen Z, Chen T, Lin J, Zhang B, Gu X.

Cancer Epidemiol. 2015 Aug;39(4):539-44. doi: 10.1016/j.canep.2015.05.010. Epub 2015 Jun 27.

PMID:
26123318
7.

Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection.

Yan CH, Lv M, Li H, Song X, Yan F, Cao S, Ren X.

J Cancer Res Clin Oncol. 2015 Aug;141(8):1371-8. doi: 10.1007/s00432-014-1902-1. Epub 2015 Jan 3.

PMID:
25555465
8.

Osteopontin is a prognostic biomarker in non-small cell lung cancer.

Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM.

BMC Cancer. 2013 Nov 11;13:540. doi: 10.1186/1471-2407-13-540.

9.

The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis.

Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ, Ling XL, Ma SC.

J Mol Histol. 2014 Oct;45(5):533-40. doi: 10.1007/s10735-014-9574-3. Epub 2014 May 10.

PMID:
24816798
10.

OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro.

Hao C, Cui Y, Hu MU, Zhi X, Zhang L, Li W, Wu W, Cheng S, Jiang WG.

Anticancer Res. 2017 May;37(5):2245-2254.

PMID:
28476789
11.

Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer.

Goparaju CM, Pass HI, Blasberg JD, Hirsch N, Donington JS.

J Thorac Oncol. 2010 Oct;5(10):1516-23. doi: 10.1097/JTO.0b013e3181eba6bd.

12.

[Protein and mRNA expression of osteopontin in lung cancer and clinical significance thereof].

Gui SY, Li HH, Zuo L, Zhou Q, Wu Q, Wang Y.

Zhonghua Yi Xue Za Zhi. 2007 Dec 4;87(45):3219-23. Chinese.

PMID:
18399118
13.

Osteopontin is associated with decreased apoptosis and αv integrin expression in lung adenocarcinoma.

Štemberger C, Matušan-Ilijaš K, Avirović M, Bulat-Kardum L, Ivančić A, Jonjić N, Lučin K.

Acta Histochem. 2014 Jan;116(1):222-9. doi: 10.1016/j.acthis.2013.07.009. Epub 2013 Aug 29.

PMID:
23992637
14.

Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer.

Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, Simmons BH, Wu A, Lee JH, Bergqvist S, Kraynov E.

J Exp Clin Cancer Res. 2012 Mar 23;31:26. doi: 10.1186/1756-9966-31-26.

15.
16.

Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection.

Sun BS, Li Y, Zhang ZF, You J, Wang CL.

Ann Thorac Surg. 2013 Dec;96(6):1943-51. doi: 10.1016/j.athoracsur.2013.07.089. Epub 2013 Oct 3.

PMID:
24094519
17.

[The expression of galectin-3 and osteopontin in occult metastasis of non-small cell lung cancer].

Liang Y, Li H, Hou SC, Hu B, Miao JB, Li T, You B, Yu LX, Wang L, Chen QR, Chen X.

Zhonghua Wai Ke Za Zhi. 2009 Jul 15;47(14):1061-3. Chinese.

PMID:
19781269
18.

Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice.

Cui R, Takahashi F, Ohashi R, Gu T, Yoshioka M, Nishio K, Ohe Y, Tominaga S, Takagi Y, Sasaki S, Fukuchi Y, Takahashi K.

Lung Cancer. 2007 Sep;57(3):302-10. Epub 2007 May 4.

PMID:
17482311
19.

Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer.

Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK.

Lung Cancer. 2007 Sep;57(3):373-80. Epub 2007 May 21.

PMID:
17513004
20.

Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study.

Zhang L, Hou X, Lu S, Rao H, Hou J, Luo R, Huang H, Zhao H, Jian H, Chen Z, Liao M, Wang X.

Lung Cancer. 2010 Jan;67(1):114-9. doi: 10.1016/j.lungcan.2009.03.017.

PMID:
19376608

Supplemental Content

Support Center